Menu

Press Releases

Date Summary View
Toggle Summary RedHill Biopharma Receives Allowance for New U.S. Patent Covering RHB-106, an Encapsulated Bowel Preparation
Once granted, the new formulation patent is expected to be valid until at least 2033 RHB-106 is an encapsulated bowel preparation with worldwide rights licensed to Salix Pharmaceuticals   RedHill and Salix recently amended their license agreement to include certain development activities, timelines ...
View HTML
Toggle Summary RedHill Biopharma Announces Closing of $25 Million Underwritten Offering
TEL-AVIV, Israel and RALEIGH, N.C. , Aug. 14, 2018 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ( Tel-Aviv Stock Exchange : RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on proprietary drugs for gastrointestinal diseases, today announced ...
View HTML
Toggle Summary RedHill Biopharma Receives Allowance for New U.S. Patent Covering RHB-104 for Crohn’s Disease and RHB-204 for NTM Infections
Once granted, the new patent, which covers both RHB-104 and RHB-204, is expected to be valid until at least 2029   RedHill recently announced positive top-line results from the randomized, double-blind, placebo-controlled MAP US Phase III study with orally-administered RHB-104 in Crohn’s disease   ...
View HTML
Toggle Summary RedHill Biopharma Announces Pricing of $25 Million Underwritten Offering
TEL-AVIV, Israel and RALEIGH, N.C. , Aug. 09, 2018 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ( Tel-Aviv Stock Exchange : RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on proprietary drugs for gastrointestinal diseases, today announced ...
View HTML
Toggle Summary RedHill Biopharma Elaborates on Its Announced Positive Top-Line Results from Phase III Study of RHB-104 in Crohn’s Disease
TEL-AVIV, Israel and RALEIGH, N.C. , Aug. 01, 2018 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) ( Tel-Aviv Stock Exchange :RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on proprietary drugs for gastrointestinal (GI) diseases, today ...
View HTML
Toggle Summary RedHill Biopharma Announces Positive Top-Line Results from Phase III Study of RHB-104 in Crohn’s Disease
Primary endpoint successfully achieved - superior remission rate at week 26 in patients treated with RHB-104 (p= 0.013)   Key secondary endpoints also met, demonstrating consistent benefit to Crohn’s disease patients treated with RHB-104   RedHill to host conference call and live webcast today, ...
View HTML
Toggle Summary RedHill Biopharma Initiates Co-Promotion of HIV/AIDS Anti-Diarrheal Drug Mytesi®
Mytesi ® is an FDA -approved anti-diarrheal prescription drug indicated for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on anti-retroviral therapy (ART) Mytesi ® is the fourth product being promoted by RedHill's gastrointestinal-focused U.S. ...
View HTML
Toggle Summary RedHill Biopharma Enrolls 400th Patient in Confirmatory Phase III Study with TALICIA® for H. pylori Infection
400 of the planned total of 444 patients have been enrolled in the ongoing confirmatory U.S. Phase III study with TALICIA ® for  H. pylori infection (ERADICATE Hp2) RedHill expects to complete enrollment in the Phase III ERADICATE Hp2 study in coming weeks and announce top-line results in Q4/2018 ...
View HTML
Toggle Summary RedHill Biopharma Announces Uplisting to Nasdaq Global Market
TEL-AVIV, Israel and RALEIGH, N.C. , July 23, 2018 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) ( Tel-Aviv Stock Exchange :RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on late clinical-stage development and commercialization of proprietary ...
View HTML
Toggle Summary RedHill Biopharma Announces Allowance of Two New RHB-104 Patents Ahead of Top-Line Phase III Results for Crohn’s Disease
RedHill has received Notices of Allowance for two new patents covering RHB-104 in the U.S. and Europe which are expected to be valid until at least 2029, once granted   Top-line results from the first Phase III study with RHB-104 for Crohn’s disease are expected to be announced in the coming weeks  ...
View HTML